Efficacy and Safety of NB003 in Patients With Advanced Gastrointestinal Stromal Tumors (GIST)
A phase 2/3 trial testing NB003 in gastrointestinal stromal tumour, now recruiting.
Overview
Efficacy and Safety of NB003 in Patients With Advanced Gastrointestinal Stromal Tumours (GIST) is a phase 2/3 interventional study registered as NCT07379047, led by Ningbo Newbay Technology Development, and recruiting when checked on 2026-09-11. Official title: A Multicenter, Open-label Clinical Study to Evaluate the Efficacy and Safety of NB003 in Patients With Advanced Gastrointestinal Stromal Tumours (GIST). Planned enrolment is 255 participants (estimated). The study started in 2026-05-11 and primary completion is expected in 2028-08-01. No results have been posted on ClinicalTrials.gov.
Similar pages
not linked directly; found by shared links- Trial(Peak) A Phase 3 Randomized Trial of CGT9486+Sunitinib vs. Sunitinib in Subjects With Gastrointestinal Stromal Tumors
Shares Gastrointestinal stromal tumour (GIST) and the tag ctgov-ingest.
- TrialA Study of IDRX-42 (GSK6042981) Versus (vs) Sunitinib in Participants With Gastrointestinal Stromal Tumors After Imatinib Therapy
Shares Gastrointestinal stromal tumour (GIST) and the tag ctgov-ingest.
- TrialA Study to Investigate Velzatinib Compared With Imatinib in Adult Participants With Previously Untreated Metastatic and/or Unresectable Gastrointestinal Stromal Tumors (StrateGIST Frontline)
Shares Gastrointestinal stromal tumour (GIST) and the tag ctgov-ingest.
- TreatmentIDRX-42
Shares Gastrointestinal stromal tumour (GIST) and the tag ctgov-ingest.
- TreatmentVelzatinib
Shares Gastrointestinal stromal tumour (GIST) and the tag ctgov-ingest.
- TreatmentBezuclastinib
Shares Gastrointestinal stromal tumour (GIST) and the tag ctgov-ingest.